Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.22 (
cdc2
)
8,319
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Exit from the cell cycle during the establishment of quiescence and upon cell differentiation requires the sustained inactivation of
CDK
complexes. Fission yeast cells deprived of
nitrogen
halt cell cycle progression in pre-Start G1, before becoming quiescent or undergoing sexual differentiation. The
CDK
inhibitor Rum1 and the APC/C activator Ste9 are fundamental for this arrest, but both are down-regulated by
CDK
complexes. Here, we show that PP2A-B56
Par1
is instrumental for Rum1 stabilization and Ste9 activation. In the absence of PP2A-B56
Par1
, cells fail to accumulate Rum1, and this results in persistent
CDK
activity, Ste9 inactivation, retention of the mitotic cyclin Cdc13, and impaired withdrawal from the cell cycle during
nitrogen
starvation. Importantly, mutation of a putative B56 interacting motif in Rum1 recapitulates these defects. These results underscore the relevance of
CDK
-counteracting phosphatases in cell differentiation, establishment of the quiescent state, and escape from it in cancer cells.
...
PMID:Requirement of PP2A-B56
Par1
for the Stabilization of the CDK Inhibitor Rum1 and Activation of APC/C
Ste9
during Pre-Start G1 in S. pombe. 3236 Dec 73
<< Previous
1
2
3
4
